Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells

Gut

Volumn 56, Issue 9, 2007, Pages 1266-1274

  Hurtado, Mariano ^a   Lozano, Juan José ^b,d   Castellanos, Elisabeth ^a   López Fernández, Luis A ^b   Harshman, Keith ^b   Martínez A, Carlos ^b   Ortiz, Angel R ^b   Thomson, Timothy M ^c   Paciucci, Rosanna ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^d CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOGENESIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

CELL DIVISION; CELL LINE, TUMOR; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; PANCREATIC NEOPLASMS; PLASMIN; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION, GENETIC;

EID: 34548128023     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.097188     Document Type: Article

References (64)

1. Lockhart AC, Rothenberg M, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-54.
2. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24.
3. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49.
4. Paciucci R, Berrozpe G, Tora M, et al. Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization. FEBS Lett 1996;385:72-6.
5. Paciucci R, Tora M, Díaz VM, et al. The plasminogen activator system in pancreas cancer: role of tPA in the invasive potential in vitro. Oncogene 1998;16:625-33.
6. Díaz VM, Planagumá J, Thomson TM, et al. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002;122:806-19.
7. Stack MS, Gray RD, Pizzo SV. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. Cancer Res 1993;53:1998-2004.
8. Jessani N, Humphrey M, McDonald WH, et al. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 2004;101:13756-61.
9. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
10. Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002;99:1359-64.
11. Liu D, Aguirre Ghiso J, Estrada Y, et al. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57.
12. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998;273:8502-7.
13. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
14. Jo M, Thomas KS, Marozkina N, et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005;280:17449-57.
15. Akassoglou K, Kombrinck KW, Degen JL, et al. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 2000;149:1157-66.
16. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.
17. Pawlak R, Rao BS, Melchor JP, et al. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci USA 2005;102:18201-6.
18. Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002;109:1571-8.
19. Matys T, Pawlak R, Matys E, et al. Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci USA 2004;101:16345- 50.
20. Medina MG, Ledesma MD, Domínguez JE, et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via ERK1/2 activation. EMBO J 2005;24:1706-16.
21. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
22. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
23. Díaz VM, Hurtado M, Thomson T, et al. Specific interaction of tissue-type plasminogen activator (tPA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004;53:993-1000.
24. Kassam G, Choi KS, Ghuman J, et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998;273:4790-9.
25. Guerra S, López-Fernandez LA, Pascual-Montano A, et al. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol 2003;77:6493-506.
26. Korc M, Magun BE. Recycling of epidermal growth factor in a human pancreatic carcinoma cell line. Proc Natl Acad Sci USA 1985;82:6172-5.
27. Bowen-Pope DF, Ross R. Platelet-derived growth factor. II. Specific binding to cultured cells. J Biol Chem 1982;257:5161-71.
28. Lozano JJ, Soler M, Bermudo R, et al. Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data. BMC Genomics 2005;6:109.
29. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003;163:505-16.
30. Liebermeister W. Linear Modes of gene expression determined by independent component analysis. Bioinformatics 2002;18:51-60.
31. Lee SI, Batzoglou S. Application of independent component analysis to microarrays. Genome Biol 2003;4:R76.
32. Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
33. Ebert M, Yokoyama M, Friess H, et al. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995;62:529-35.
34. Fambrough D, McClure K, Kazlauskas A, et al. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 1999;97:727-41.
35. Saito Y, Haendeler J, Hojo Y, et al. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001;21:6387-94.
36. Carter RE, Sorkin A. Endocytosis of functional epidermal growth factor receptor-green fluorescent protein chimera. J Biol Chem 1998;273:35000-7.
37. Hunyady L, Baukal AJ, Gaborik Z, et al. Differential PI 3-kinase dependence of early and late phases of recycling of the internalized AT1 angiotensin receptor. J Cell Biol 2002;157:1211-22.
38. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-81.
39. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4.
40. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metailoproteinase by tissue plasminogen activator. Nat Med 2003;9:1313-7.
41. Zhao BQ, Ikeda Y, Ihara H, et al. Essential role of endogenous tissue plasminogen activator through matrix metailoproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004;103:2610-16.
42. Liu Z, Li N, Diaz IA, et al. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005;115:879-87.
43. Mitamura T, Higashiyama S, Taniguchi N, et al. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995;270:1015-9.
44. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992;166:7-12.
45. Pawson T, Saxton TM. Signaling networks - do all roads lead to the same genes? Cell, 1999;97:675-8.
46. Hughes TR, Marton MJ, Jones AR, et al. Functional discovery via a compendium of expression profiles. Cell 2000;102:109-26.
47. Sionim DK. From patterns to pathways: gene expression data analysis comes of age. Nat Genet 2002;32(Suppl):502-8.
48. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005;3:281-94.
49. El-Shewy HM, Kelly FL, Barki-Harrington L, et al. Ectodomain shedding-dependent transactivation of epidermal growth factor receptors in response to insulin-like growth factor type I. Mol Endocrinol 2004;11:2727-39.
50. Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res 2004;2:514-22.
51. Islam R, Kristiansen LV, Romani S, et al. Activation of EGF receptor kinase by L1-mediated homophilic cell interactions. Mol Biol Cell 2004;15:2003-12.
52. Sieg DJ, Christof R. Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nature Cell Biol 2000;2:249-56.
53. Roelle S, Grosse R, Aigner A, et al. Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 2003;278:47307-18.
54. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metailoproteinase cleavage of pro hb-EGF. Nature 1999;402:884-8.
55. Luttrell LM, Della Rocca GJ, van Biesen T, et al. G-betagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G proteincoupled receptor-mediated Ras activation. J Biol Chem 1997;272:4637-44.
56. Hu K, Yang J, Tanaka S, et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006;281:2120-7.
57. Takada M, Hirata K, Ajiki T, et al. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004;51:928-30.
58. Jorgensen E, Nexo E, Poulsen SS. The membrane fraction of homogenized rat kidney contains an enzyme that releases epidermal growth factor from the kidney membranes. Biochem Biophys Acta 1991;1074:284-8.
59. Schaudies RP, Johnson JP. Increased soluble EGF after ischemia is accompanied by a decrease in membrane-associated precursors. Am J Physiol 1993;264:F523-31.
60. Fredriksson L, Li H, Fieber C, et al. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004;23:3793- 802.
61. Smith J, Dryneck R, Korc M. Production of transforming growth factor α in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 1987;84:7567-70.
62. Kobrin MS, Funatomi H, Friess H, et al. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994;202:1705-9.
63. Yokoi K, Sasaki T, Bucana CD, et al. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005;65:10371-80.
64. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (hb-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-5.